FTC Demands More Info On $1.6B Charles River Deal

Law360, New York (July 13, 2010, 11:19 AM EDT) -- The Federal Trade Commission is seeking additional information on Charles River Laboratories International Inc.'s plan to buy China's WuXi PharmaTech (Cayman) Inc. in a $1.6 billion cash-and-stock merger.

Both companies said in regulatory filings Tuesday that they had received a request from the FTC for additional information on WuXi's viral clearance services, cell line characterization services and lot release testing services businesses.

The second request extends the waiting period for antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act to 30 days after the companies have complied...
To view the full article, register now.